CA
TNDM icon

CastleArk Alternatives’s Tandem Diabetes Care TNDM Stock Holding History

CastleArk Alternatives’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-30,990
Closed -$3.7M – 264
2021
Q3 		$3.7M Buy
+30,990
New +$3.41M 0.14% 153

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

CastleArk Alternatives's TNDM Position: Q4 2021 in Review

CastleArk Alternatives sold out of Tandem Diabetes Care (TNDM) in Q4 2021, closing a stake of 30,990 shares — an estimated $3.7M sold.

CastleArk Alternatives first reported a position in TNDM in Q3 2021 and held it in 1 quarter. The position peaked at $3.7M in Q3 2021. 388 funds tracked by Wall St. Rank hold TNDM as of Q4 2021.

  • CastleArk Alternatives reported no remaining Tandem Diabetes Care position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 30,990 Tandem Diabetes Care shares in Q4 2021, an estimated $3.7M.
  • CastleArk Alternatives first reported a position in Tandem Diabetes Care in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's Tandem Diabetes Care position peaked at $3.7M in Q3 2021.
  • 388 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.